Used in the treatment of early-stage Alzheimer’s disease, this antibody targets and promotes the clearance of amyloid-beta plaques in the brain, particularly the pyroglutamate-modified form found in insoluble plaques. By binding to these pathological deposits, it helps reduce plaque burden, which is associated with slowing cognitive decline. It is applied in clinical settings through intravenous infusion and is part of immunotherapeutic strategies aimed at modifying the disease progression rather than just managing symptoms. Its use supports early diagnosis and intervention, often in combination with amyloid PET imaging to confirm plaque presence.